| Literature DB >> 26104939 |
Daniel J Krauss1, Chen Hu2, Jean-Paul Bahary3, Luis Souhami4, Elizabeth M Gore5, Susan Maria Jacinta Chafe6, Mark H Leibenhaut7, Samir Narayan8, Javier Torres-Roca9, Jeff Michalski10, Kenneth L Zeitzer11, Viroon Donavanik12, Howard Sandler13, David G McGowan6, Christopher U Jones7, William U Shipley14.
Abstract
PURPOSE: The purpose of this study was to assess the association between positive post-radiation therapy (RT) biopsy results and subsequent clinical outcomes in males with localized prostate cancer. METHODS AND MATERIALS: Radiation Therapy Oncology Group study 94-08 analyzed 1979 males with prostate cancer, stage T1b-T2b and prostate-specific antigen concentrations of ≤ 20 ng/dL, to investigate whether 4 months of total androgen suppression (TAS) added to RT improved survival compared to RT alone. Patients randomized to receive TAS received flutamide with luteinizing hormone releasing hormone (LHRH) agonist. According to protocol, patients without evidence of clinical recurrence or initiation of additional endocrine therapy underwent repeat prostate biopsy 2 years after RT completion. Statistical analysis was performed to evaluate the impact of positive post-RT biopsy results on clinical outcomes.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26104939 PMCID: PMC4480595 DOI: 10.1016/j.ijrobp.2015.03.017
Source DB: PubMed Journal: Int J Radiat Oncol Biol Phys ISSN: 0360-3016 Impact factor: 7.038